Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab for EBV Reactivation Post-Transplant
NCT04690036Phase 1Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in Epstein-Barr virus infection, sponsored by Beijing Friendship Hospital. Primary endpoint: EBV-DNA turn negative at 4 weeks. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT04690036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690036.